

11th July, 2017

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400001 Scrip Code: BSE - AJANTPHARM 532331	National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: NSE AJANTPHARM EQ
---	---

Re: Disclosures under Regulation 7(2)(a) & (b) of SEBI (Prohibition of Insider Trading) Regulations, 2015 and Regulation 30 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

We have to inform that M/s. Ganga Exports, a promoter group entity has sold 27,00,000 equity shares of the company representing 3.07% of paid up capital.

Pursuant to Regulation 7(2)(a) & (b) of SEBI (Prohibition of Insider Trading) Regulations, 2015, please find enclosed herewith disclosures of change in shareholdings received from promoters of the Company.

Further, Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, please also find enclosed herewith press release being issued in this regard.

Thanking You,

Yours faithfully,



GAURANG SHAH
AVP - Legal &
Company Secretary

Encl.: a/a

Form C
Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015
[Regulation 7 (2) read with Regulation 6(2) - Continual disclosure]


Name of the Company: Ajanta Pharma Limited
ISIN of the Company: INE031B01049

Details of change in holding of Securities of Promoter, Employee or Director of a listed company and other such persons as mentioned in Regulation 6(2).

Name, PAN, CIN/DIN & Address with contact nos.	Category of Person (Promoters/ MP/Directors / Immediate Relatives/ Others etc.)	Securities held prior to acquisition/disposal		Securities acquired/disposed				Securities held post acquisition/disposal		Date of allotment- advice/acquisition of shares/sale of shares specify		Date of Intimation to the Company	Mode of acquisition/disposal (on market/public rights/preferential offer/off-market/inter-se transfer, SEOP's etc.)	Trading in derivatives (Specify type of contract, futures or Options etc.)						Exchange on which the trade was executed
		Type of security (For eg. – Shares, Warrants, Convertible Debentures etc.)	No and % of shareholding	Type of security (For eg. – Shares, Warrants, Convertible Debentures etc.)	No.	Value	Transaction Type (Buy/Sale/ Pledge/Revoked/invoke)	Type of security (For eg.-share, Warrants, convertible debentures etc.)	No. and % of shareholding	From	To			Types of contract	Contract specifications	Buy		Sell		
																Nominal Value	Number of units (contracts * lot size)	Nominal Value	Number of units (contracts *lot size)	
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
Ganga Exports represented by Yogesh Agrawal, Rajesh Agrawal, Ravi Agrawal & Aayush Agrawal; 98, Industrial Area, Charkop, Kandivli (West), Mumbai - 400 067 Pan no.AACFG3419P	Promoter	Shares	51,37,500 (5.84%)	Shares	215,000	Rs. 33.33 crores	Sale	Shares	49,22,500 (5.59%)	10.07.2017	10.07.2017	11.07.2017	Sale of shares	-	-	-	-	-	-	BSE
		Shares	49,22,500 (5.59%)	Shares	2,485,000	Rs. 372.77crs	Sale	Shares	24,37,500 (3.77%)	11.07.2017	11.07.2017	11.07.2017	Sale of shares							

Note: "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI(Prohibition of Insider Trading) Regulations, 2015

Signature:



Designation: Yogesh Agrawal, partner of Ganga Exports

Date: 11.07.2017

Place: Mumbai

Note: Rounding-off of percentages could result in arithmetic differences.

Press Release**Promoters Sells Small Stake in Ajanta Pharma**

Mumbai, 11th July, 2017: Mr. Yogesh M. Agrawal, Managing Director of Ajanta Pharma Limited ("APL" or "Company") has informed the Company that promoters have sold 27,00,000 equity shares in APL, representing about 3.07% of APL's equity shares. Consequent to sale, promoter holding has come down from 73.78% to 70.71% stake in APL.

This sale has been done to provide liquidity to the promoters and the proceeds will be utilized for personal use.

Mr. Yogesh M. Agrawal, Managing Director, Ajanta Pharma Limited, and also a part of the promoter group, said "APL is a standout success and we are immensely proud of our company's journey so far. We believe that we have the right business strategy and management team to deliver our growth aspirations. I am excited to continue to steer APL's next phase of growth."

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa. Many of company's products are 1st to market and are leading in their sub-therapeutic segments.

Company's state of the art R&D centres for formulation development and API are located at Mumbai, having a team of 800+ scientists. Company has 7 world class manufacturing facilities located in India and Mauritius.

For last 5 years, company has posted healthy performance with its consolidated total income growing at 21% CAGR and net profit at 46% CAGR.

For more details visit www.ajantapharma.com

For regular updates follow us on twitter– www.twitter.com/ajantapharmaltd

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331
Corporate Identity Number (CIN): L24230MH1979PLC022059

Safe Harbour Statement